METTL17
gene geneOn this page
Also known as FLJ20859
Summary
METTL17 (methyltransferase like 17, HGNC:19280) is a protein-coding gene on chromosome 14q11.2, encoding Ribosome assembly protein METTL17, mitochondrial (Q9H7H0). Mitochondrial ribosome (mitoribosome) assembly factor. It is a selective cancer dependency (DepMap: 51.2% of cell lines).
Enables 4 iron, 4 sulfur cluster binding activity. Involved in mitochondrial small ribosomal subunit assembly. Located in nucleoplasm.
Source: NCBI Gene 64745 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 59 total
- Cancer dependency (DepMap): dependent in 51.2% of screened cell lines
- MANE Select transcript:
NM_022734
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:19280 |
| Approved symbol | METTL17 |
| Name | methyltransferase like 17 |
| Location | 14q11.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ20859 |
| Ensembl gene | ENSG00000165792 |
| Ensembl biotype | protein_coding |
| OMIM | 616091 |
| Entrez | 64745 |
Gene structure
Transcript identifiers
Ensembl transcripts: 28 — 12 retained_intron, 11 protein_coding, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined
ENST00000339374, ENST00000382985, ENST00000553389, ENST00000553441, ENST00000553536, ENST00000553564, ENST00000554283, ENST00000554354, ENST00000554588, ENST00000554751, ENST00000554849, ENST00000554949, ENST00000554985, ENST00000555177, ENST00000555390, ENST00000555533, ENST00000555640, ENST00000555670, ENST00000555902, ENST00000556442, ENST00000556670, ENST00000556733, ENST00000557279, ENST00000557550, ENST00000557701, ENST00000908545, ENST00000908546, ENST00000967486
RefSeq mRNA: 2 — MANE Select: NM_022734
NM_001029991, NM_022734
CCDS: CCDS41913, CCDS9562
Canonical transcript exons
ENST00000339374 — 14 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003483715 | 20995901 | 20995951 |
| ENSE00003483929 | 20996785 | 20997035 |
| ENSE00003503063 | 20992541 | 20992622 |
| ENSE00003519874 | 20989980 | 20990077 |
| ENSE00003522160 | 20993969 | 20994063 |
| ENSE00003524955 | 20990464 | 20990598 |
| ENSE00003565571 | 20993118 | 20993191 |
| ENSE00003601069 | 20996527 | 20996711 |
| ENSE00003608411 | 20994794 | 20994901 |
| ENSE00003616189 | 20990230 | 20990383 |
| ENSE00003663884 | 20996209 | 20996292 |
| ENSE00003669192 | 20995165 | 20995233 |
| ENSE00003675887 | 20992124 | 20992205 |
| ENSE00003788563 | 20994543 | 20994613 |
Expression profiles
Bgee: expression breadth ubiquitous, 269 present calls, max score 98.37.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.2430 / max 141.7376, expressed in 1815 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 138491 | 29.2430 | 1815 |
Top tissues by expression
280 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right adrenal gland cortex | UBERON:0035827 | 98.37 | gold quality |
| right adrenal gland | UBERON:0001233 | 98.22 | gold quality |
| right uterine tube | UBERON:0001302 | 97.87 | gold quality |
| left adrenal gland | UBERON:0001234 | 97.79 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 97.77 | gold quality |
| metanephros cortex | UBERON:0010533 | 97.76 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 97.48 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 97.46 | gold quality |
| adrenal cortex | UBERON:0001235 | 97.44 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 97.44 | gold quality |
| cerebellar cortex | UBERON:0002129 | 97.38 | gold quality |
| tibial nerve | UBERON:0001323 | 97.31 | gold quality |
| body of uterus | UBERON:0009853 | 97.25 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 97.18 | gold quality |
| transverse colon | UBERON:0001157 | 97.17 | gold quality |
| body of pancreas | UBERON:0001150 | 97.15 | gold quality |
| endocervix | UBERON:0000458 | 97.12 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 97.07 | gold quality |
| left ovary | UBERON:0002119 | 97.04 | gold quality |
| right ovary | UBERON:0002118 | 97.03 | gold quality |
| adrenal gland | UBERON:0002369 | 97.01 | gold quality |
| ectocervix | UBERON:0012249 | 96.99 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 96.94 | gold quality |
| apex of heart | UBERON:0002098 | 96.93 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 96.87 | gold quality |
| secondary oocyte | CL:0000655 | 96.84 | gold quality |
| skin of leg | UBERON:0001511 | 96.82 | gold quality |
| skin of abdomen | UBERON:0001416 | 96.75 | gold quality |
| minor salivary gland | UBERON:0001830 | 96.75 | gold quality |
| body of stomach | UBERON:0001161 | 96.63 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 5.74 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
13 targeting METTL17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4795-3P | 100.00 | 74.62 | 4024 |
| HSA-MIR-126-5P | 100.00 | 72.71 | 3180 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-216A-5P | 99.50 | 68.02 | 1288 |
| HSA-MIR-1207-5P | 99.49 | 69.11 | 2983 |
| HSA-MIR-371A-5P | 99.08 | 66.51 | 1914 |
| HSA-MIR-4477A | 98.83 | 69.75 | 2952 |
| HSA-MIR-6826-3P | 98.19 | 66.32 | 1153 |
| HSA-MIR-634 | 97.74 | 67.11 | 818 |
| HSA-MIR-3622A-5P | 97.43 | 67.11 | 356 |
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 51.2% of screened cell lines.
Literature-anchored findings (GeneRIF, showing 5)
- Possible component of the small subunit of the mitochondrial ribosome, has similarity to yeast Rsm22 (Ykl155c) mitochondrial ribosomal protein. (PMID:11278769)
- METT11D1 mutations could not explain phenotype of patients with combined oxidative phosphorylation system deficiencies. (PMID:24137763)
- METTL17 is a novel coactivator of estrogen receptors and may play a role in breast tumorigenesis. (PMID:26488768)
- efects of mitochondrial ribosome caused by deletion of Mettl17 lead to the impaired translation of mitochondrial protein-coding genes, resulting in significant changes in mitochondrial oxidative phosphorylation and cellular metabolome, which are important for mESC pluripotency (PMID:31487196)
- METTL17 coordinates ferroptosis and tumorigenesis by regulating mitochondrial translation in colorectal cancer. (PMID:38377789)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | mettl17 | ENSDARG00000103889 |
| mus_musculus | Mettl17 | ENSMUSG00000004561 |
| rattus_norvegicus | Mettl17 | ENSRNOG00000025512 |
| drosophila_melanogaster | CG13126 | FBGN0032168 |
Paralogs (1): COX11 (ENSG00000166260)
Protein
Protein identifiers
Ribosome assembly protein METTL17, mitochondrial — Q9H7H0 (reviewed: Q9H7H0)
Alternative names: False p73 target gene protein, Methyltransferase 11 domain-containing protein 1, Methyltransferase-like protein 17, Protein RSM22 homolog, mitochondrial
All UniProt accessions (9): A0A0S2Z5L8, A0A0S2Z5V5, B4E298, Q9H7H0, G3V353, G3V3X6, G3V4H5, G3V4P2, H0YJW1
UniProt curated annotations — full annotation on UniProt →
Function. Mitochondrial ribosome (mitoribosome) assembly factor. Binds at the interface of the head and body domains of the mitochondrial small ribosomal subunit (mt-SSU), occluding the mRNA channel and preventing compaction of the head domain towards the body. Probable inactive methyltransferase: retains the characteristic folding and ability to bind S-adenosyl-L-methionine, but it probably lost its methyltransferase activity.
Subunit / interactions. Associates with the mitochondrial ribosome (mitoribosome).
Subcellular location. Mitochondrion matrix.
Domain organisation. [4Fe-4S] cluster-binding is essential for its ability to promote assembly of the mitochondrial ribosome (mitoribosome).
Similarity. Belongs to the methyltransferase superfamily. Rsm22 family.
Isoforms (3)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9H7H0-1 | 1 | yes |
| Q9H7H0-2 | 2 | |
| Q9H7H0-3 | 3 |
RefSeq proteins (2): NP_001025162, NP_073571* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR015324 | Ribosomal_Rsm22-like | Family |
| IPR029063 | SAM-dependent_MTases_sf | Homologous_superfamily |
| IPR052571 | Mt_RNA_Methyltransferase | Family |
Pfam: PF09243
UniProt features (57 total): strand 20, helix 14, mutagenesis site 5, turn 5, binding site 4, sequence variant 3, sequence conflict 2, splice variant 2, transit peptide 1, chain 1
Structure
Experimental structures (PDB)
6 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 8CSS | ELECTRON MICROSCOPY | 2.36 |
| 8CSQ | ELECTRON MICROSCOPY | 2.54 |
| 8CSR | ELECTRON MICROSCOPY | 2.54 |
| 8CSP | ELECTRON MICROSCOPY | 2.66 |
| 8CST | ELECTRON MICROSCOPY | 2.85 |
| 8CSU | ELECTRON MICROSCOPY | 3.03 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9H7H0-F1 | 86.26 | 0.71 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Ligand- & substrate-binding residues (4): 333; 339; 347; 404
Mutagenesis-validated functional residues (5):
| Position | Phenotype |
|---|---|
| 333 | abolished iron-sulfur-binding, leading to impaired ability to promote mitochondrial ribosome assembly; when associated w |
| 339 | abolished iron-sulfur-binding, leading to impaired ability to promote mitochondrial ribosome assembly; when associated w |
| 347 | abolished iron-sulfur-binding, leading to impaired ability to promote mitochondrial ribosome assembly; when associated w |
| 404 | abolished iron-sulfur-binding, leading to impaired ability to promote mitochondrial ribosome assembly; when associated w |
| 424–426 | impaired ability to promote mitochondrial ribosome assembly. |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 117 (showing top):
GSE45365_NK_CELL_VS_CD11B_DC_UP, GOBP_RIBOSOME_BIOGENESIS, TAATAAT_MIR126, GCM_GSPT1, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, GOBP_RIBOSOME_ASSEMBLY, GOBP_TRANSLATION, GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS, GOBP_PROTEIN_RNA_COMPLEX_ORGANIZATION, GOBP_ORGANELLE_ASSEMBLY, GCM_NUMA1, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, GCM_NF2, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS
GO Biological Process (4): translation (GO:0006412), ribosomal small subunit biogenesis (GO:0042274), mitochondrial small ribosomal subunit assembly (GO:0180026), methylation (GO:0032259)
GO Molecular Function (9): metal ion binding (GO:0046872), 4 iron, 4 sulfur cluster binding (GO:0051539), mitochondrial ribosome binding (GO:0097177), S-adenosyl-L-methionine binding (GO:1904047), protein binding (GO:0005515), methyltransferase activity (GO:0008168), transferase activity (GO:0016740), small molecule binding (GO:0036094), iron-sulfur cluster binding (GO:0051536)
GO Cellular Component (4): nucleoplasm (GO:0005654), mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759), intracellular organelle lumen (GO:0070013)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cation binding | 2 |
| binding | 2 |
| peptidyltransferase activity | 1 |
| translational initiation | 1 |
| translational elongation | 1 |
| translational termination | 1 |
| macromolecule biosynthetic process | 1 |
| protein metabolic process | 1 |
| protein biosynthetic process | 1 |
| ribonucleoprotein complex biogenesis | 1 |
| ribosome biogenesis | 1 |
| ribosomal small subunit assembly | 1 |
| mitochondrial ribosome assembly | 1 |
| metabolic process | 1 |
| iron-sulfur cluster binding | 1 |
| ribosome binding | 1 |
| sulfur compound binding | 1 |
| transferase activity, transferring one-carbon groups | 1 |
| catalytic activity | 1 |
| metal cluster binding | 1 |
| nuclear lumen | 1 |
| cellular anatomical structure | 1 |
| cytoplasm | 1 |
| intracellular membrane-bounded organelle | 1 |
| mitochondrion | 1 |
| intracellular organelle lumen | 1 |
| intracellular organelle | 1 |
| organelle lumen | 1 |
Protein interactions and networks
STRING
1508 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| METTL17 | NTMT1 | Q9BV86 | 606 |
| METTL17 | METTL27 | Q8N6F8 | 584 |
| METTL17 | METTL15 | A6NJ78 | 581 |
| METTL17 | METTL5 | Q9NRN9 | 578 |
| METTL17 | METTL18 | O95568 | 557 |
| METTL17 | METTL9 | Q9H1A3 | 532 |
| METTL17 | NTMT2 | Q5VVY1 | 526 |
| METTL17 | CHCHD1 | Q96BP2 | 519 |
| METTL17 | METTL25 | Q8N6Q8 | 505 |
| METTL17 | TMT1A | Q9H8H3 | 497 |
| METTL17 | TMEM126A | Q9H061 | 488 |
| METTL17 | ESR2 | Q92731 | 483 |
| METTL17 | METTL26 | Q96S19 | 480 |
| METTL17 | TRUB2 | O95900 | 472 |
| METTL17 | METTL1 | Q9UBP6 | 455 |
| METTL17 | RPUSD3 | Q6P087 | 455 |
IntAct
164 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| METTL17 | TRAF1 | psi-mi:“MI:0915”(physical association) | 0.780 |
| METTL17 | CALCOCO2 | psi-mi:“MI:0915”(physical association) | 0.780 |
| METTL17 | PNMA1 | psi-mi:“MI:0915”(physical association) | 0.780 |
| METTL17 | CEP70 | psi-mi:“MI:0915”(physical association) | 0.780 |
| TRAF1 | METTL17 | psi-mi:“MI:0915”(physical association) | 0.780 |
| CALCOCO2 | METTL17 | psi-mi:“MI:0915”(physical association) | 0.780 |
| PNMA1 | METTL17 | psi-mi:“MI:0915”(physical association) | 0.780 |
| CEP70 | METTL17 | psi-mi:“MI:0915”(physical association) | 0.780 |
| TRIP6 | METTL17 | psi-mi:“MI:0915”(physical association) | 0.740 |
| METTL17 | TFIP11 | psi-mi:“MI:0915”(physical association) | 0.740 |
BioGRID (470): METTL17 (Two-hybrid), METTL17 (Two-hybrid), METTL17 (Two-hybrid), METTL17 (Two-hybrid), METTL17 (Two-hybrid), METTL17 (Two-hybrid), METTL17 (Two-hybrid), CEP70 (Two-hybrid), KRT40 (Two-hybrid), SPERT (Two-hybrid), METTL17 (Affinity Capture-MS), METTL17 (Two-hybrid), METTL17 (Two-hybrid), TRIP6 (Two-hybrid), METTL17 (Affinity Capture-MS)
ESM2 similar proteins: A0PJW6, A5PJW2, B3DI94, B5DFG1, O00411, O95382, P49753, Q059A4, Q0V9C9, Q3SX05, Q4KLZ1, Q4KM93, Q4R5Q4, Q4VAE3, Q53S58, Q5EA71, Q5T1A1, Q5XIC2, Q643R3, Q66LN0, Q6DC58, Q6NVG1, Q76MJ5, Q7YS91, Q80YU0, Q863F8, Q8BPE4, Q8BWM0, Q8N159, Q8NFF5, Q8VCA6, Q8VD26, Q921N7, Q96AN5, Q96KR6, Q99MQ3, Q9BQ95, Q9BUB7, Q9BYK8, Q9CQE2
Diamond homologs: Q2TBP8, Q3U2U7, Q9H7H0
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 123 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Mitochondrial translation | 17 | 27.9× | 1e-18 |
| Mitochondrial translation initiation | 18 | 27.2× | 3e-19 |
| Mitochondrial translation elongation | 18 | 27.2× | 3e-19 |
| Mitochondrial ribosome-associated quality control | 18 | 26.3× | 3e-19 |
| Mitochondrial translation termination | 18 | 23.5× | 1e-18 |
| SARS-CoV-1 modulates host translation machinery | 6 | 22.1× | 4e-06 |
| Eukaryotic Translation Initiation | 5 | 18.4× | 9e-05 |
| Cap-dependent Translation Initiation | 5 | 18.4× | 9e-05 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| mitochondrial translation | 18 | 27.4× | 1e-18 |
| cytoplasmic translation | 9 | 14.6× | 2e-06 |
| translation | 16 | 14.4× | 5e-12 |
| ribosomal small subunit biogenesis | 6 | 12.0× | 2e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
59 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 36 |
| Likely benign | 3 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1363 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 14:20990384:G:GA | donor_loss | 1.0000 |
| 14:20990385:T:A | donor_loss | 1.0000 |
| 14:20990386:GAG:G | donor_loss | 1.0000 |
| 14:20990387:AGTAA:A | donor_loss | 1.0000 |
| 14:20992123:GACTT:G | acceptor_gain | 1.0000 |
| 14:20992204:AG:A | donor_loss | 1.0000 |
| 14:20992206:G:GC | donor_loss | 1.0000 |
| 14:20992206:G:GG | donor_gain | 1.0000 |
| 14:20992207:T:A | donor_loss | 1.0000 |
| 14:20993964:CTTA:C | acceptor_loss | 1.0000 |
| 14:20993965:TTAG:T | acceptor_loss | 1.0000 |
| 14:20993966:TA:T | acceptor_loss | 1.0000 |
| 14:20993967:A:AG | acceptor_gain | 1.0000 |
| 14:20993968:G:GG | acceptor_gain | 1.0000 |
| 14:20994061:AAGG:A | donor_loss | 1.0000 |
| 14:20994062:AGGT:A | donor_loss | 1.0000 |
| 14:20994064:GT:G | donor_loss | 1.0000 |
| 14:20994065:T:G | donor_loss | 1.0000 |
| 14:20995156:T:TA | acceptor_gain | 1.0000 |
| 14:20995158:T:TA | acceptor_gain | 1.0000 |
| 14:20995159:GAACA:G | acceptor_loss | 1.0000 |
| 14:20995162:CAGGT:C | acceptor_loss | 1.0000 |
| 14:20995163:A:AG | acceptor_gain | 1.0000 |
| 14:20995163:A:AT | acceptor_loss | 1.0000 |
| 14:20995164:G:GG | acceptor_gain | 1.0000 |
| 14:20995232:AGGT:A | donor_loss | 1.0000 |
| 14:20995233:GGTAA:G | donor_loss | 1.0000 |
| 14:20995234:G:GA | donor_loss | 1.0000 |
| 14:20995234:G:GG | donor_gain | 1.0000 |
| 14:20995892:T:TA | acceptor_gain | 1.0000 |
AlphaMissense
2935 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 14:20996802:C:A | A428D | 0.985 |
| 14:20996209:T:C | C333R | 0.984 |
| 14:20993160:G:C | D191H | 0.983 |
| 14:20996810:A:C | S431R | 0.983 |
| 14:20996812:C:A | S431R | 0.983 |
| 14:20996812:C:G | S431R | 0.983 |
| 14:20993190:T:A | W201R | 0.982 |
| 14:20993190:T:C | W201R | 0.982 |
| 14:20996227:T:C | C339R | 0.980 |
| 14:20996551:T:C | F369L | 0.979 |
| 14:20996553:C:A | F369L | 0.979 |
| 14:20996553:C:G | F369L | 0.979 |
| 14:20996647:T:C | C401R | 0.976 |
| 14:20996552:T:C | F369S | 0.975 |
| 14:20995175:A:T | E296V | 0.974 |
| 14:20996605:C:A | R387S | 0.974 |
| 14:20996792:T:G | Y425D | 0.970 |
| 14:20995218:G:C | R310S | 0.969 |
| 14:20995218:G:T | R310S | 0.969 |
| 14:20994878:T:A | W285R | 0.968 |
| 14:20994878:T:C | W285R | 0.968 |
| 14:20992557:A:C | S155R | 0.967 |
| 14:20992559:C:A | S155R | 0.967 |
| 14:20992559:C:G | S155R | 0.967 |
| 14:20996227:T:A | C339S | 0.967 |
| 14:20996228:G:C | C339S | 0.967 |
| 14:20996656:T:C | C404R | 0.967 |
| 14:20993985:T:A | W207R | 0.966 |
| 14:20993985:T:C | W207R | 0.966 |
| 14:20994055:T:C | L230P | 0.965 |
dbSNP variants (sampled 300 via entrez): RS1000185701 (14:20992853 C>A,G), RS1000317830 (14:20993781 CTT>C,CT,CTTT,CTTTT,CTTTTT), RS1000544424 (14:20988754 C>G,T), RS1000662131 (14:20992437 G>A), RS1001307849 (14:20988179 A>T), RS1001319531 (14:20993650 T>G), RS1001515347 (14:20990173 G>A,T), RS1001961943 (14:20989588 T>A), RS1002218070 (14:20993625 C>T), RS1002666507 (14:20990284 C>G,T), RS1002727902 (14:20994726 T>C), RS1003316933 (14:20996067 A>G), RS1003594719 (14:20992034 G>A,C,T), RS1003610356 (14:20996374 G>A,C,T), RS1004050091 (14:20990932 G>GT)
Disease associations
OMIM: gene MIM:616091 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST009304_1 | Degraded stimulus continuous performance test score | 7.000000e-06 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007636 | attention function measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
24 total (human), top 24 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, increases abundance | 2 |
| Air Pollutants | decreases expression, affects cotreatment, increases abundance, increases oxidation | 2 |
| alpha-pinene | increases abundance, affects cotreatment, increases oxidation | 1 |
| bisphenol A | decreases expression | 1 |
| methacrylaldehyde | affects cotreatment, increases oxidation, increases abundance | 1 |
| K 7174 | decreases expression | 1 |
| Decitabine | affects expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Acrolein | affects cotreatment, increases oxidation, increases abundance | 1 |
| Arsenic | decreases expression, increases abundance | 1 |
| Cadmium | increases abundance, increases expression | 1 |
| Cisplatin | affects expression | 1 |
| Doxorubicin | decreases expression | 1 |
| Ozone | affects cotreatment, increases oxidation, increases abundance | 1 |
| Ribonucleotides | affects binding | 1 |
| Thiram | decreases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Valproic Acid | increases methylation | 1 |
| Aflatoxin B1 | increases methylation | 1 |
| Sodium Selenite | decreases expression | 1 |
| Antirheumatic Agents | increases expression | 1 |
| Cadmium Chloride | increases abundance, increases expression | 1 |
| Particulate Matter | decreases expression, increases abundance | 1 |
| Volatile Organic Compounds | affects cotreatment, increases oxidation | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.